Limits...
Impact of COX2 genotype, ER status and body constitution on risk of early events in different treatment groups of breast cancer patients.

Markkula A, Simonsson M, Rosendahl AH, Gaber A, Ingvar C, Rose C, Jernström H - Int. J. Cancer (2014)

Bottom Line: The COX2 rs5277 (306G>C) polymorphism has been associated with inflammation-associated cancers.Minor allele(C) frequency was 16.1%.Chemotherapy-treated G/G-carriers with a breast volume ≥ 850 ml had an increased risk of early events irrespective of ER status, adjusted HR 8.99 (1.14-70.89).

View Article: PubMed Central - PubMed

Affiliation: Division of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.

Show MeSH

Related in: MedlinePlus

Kaplan–Meier estimates of breast cancer-free survival among endocrine-treated patients with ER-positive tumors in relation to COX2 rs5277 genotype and breast volume. As this is an ongoing cohort, there are fewer patients with longer follow-up times. (a) In relation to breast volume (Log Rank; p = 0.006). (b) In relation to COX2 rs5277 genotype (Log Rank; p = 0.19). (c) In relation to breast volume and COX2 rs5277 genotype (Log Rank, 3 df; p = 0.005). Adjusted HR 2.30 (95% CI 1.12–4.75; p = 0.024).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4225481&req=5

fig04: Kaplan–Meier estimates of breast cancer-free survival among endocrine-treated patients with ER-positive tumors in relation to COX2 rs5277 genotype and breast volume. As this is an ongoing cohort, there are fewer patients with longer follow-up times. (a) In relation to breast volume (Log Rank; p = 0.006). (b) In relation to COX2 rs5277 genotype (Log Rank; p = 0.19). (c) In relation to breast volume and COX2 rs5277 genotype (Log Rank, 3 df; p = 0.005). Adjusted HR 2.30 (95% CI 1.12–4.75; p = 0.024).

Mentions: The impact of COX2 genotype and body size on early events in endocrine-treated patients with ER-positive tumors was investigated. Endocrine-treated patients with a breast volume ≥850 ml had an increased risk of early events compared to endocrine-treated patients with a breast volume <850 ml ( Fig. 4a; Log Rank 1 df; p = 0.006). C-allele carriers did not have a significantly increased risk of early events compared to G/G carriers ( Fig. 4b; Log Rank 1 df; p = 0.19). However, C-allele carriers with a breast volume ≥850 ml had an increased risk of early events ( Fig. 4c; Log Rank 3 df; p = 0.005). The results were not dependent on whether the patients had received aromatase inhibitors (AI) or tamoxifen. In a multivariate model, C-allele carriers with a breast volume ≥850 ml had a more than 2-fold increased risk of early events compared to GG carriers with a breast volume ≥850 ml (adjusted HR 2.30; 95% CI 1.12–4.75; p = 0.024).


Impact of COX2 genotype, ER status and body constitution on risk of early events in different treatment groups of breast cancer patients.

Markkula A, Simonsson M, Rosendahl AH, Gaber A, Ingvar C, Rose C, Jernström H - Int. J. Cancer (2014)

Kaplan–Meier estimates of breast cancer-free survival among endocrine-treated patients with ER-positive tumors in relation to COX2 rs5277 genotype and breast volume. As this is an ongoing cohort, there are fewer patients with longer follow-up times. (a) In relation to breast volume (Log Rank; p = 0.006). (b) In relation to COX2 rs5277 genotype (Log Rank; p = 0.19). (c) In relation to breast volume and COX2 rs5277 genotype (Log Rank, 3 df; p = 0.005). Adjusted HR 2.30 (95% CI 1.12–4.75; p = 0.024).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4225481&req=5

fig04: Kaplan–Meier estimates of breast cancer-free survival among endocrine-treated patients with ER-positive tumors in relation to COX2 rs5277 genotype and breast volume. As this is an ongoing cohort, there are fewer patients with longer follow-up times. (a) In relation to breast volume (Log Rank; p = 0.006). (b) In relation to COX2 rs5277 genotype (Log Rank; p = 0.19). (c) In relation to breast volume and COX2 rs5277 genotype (Log Rank, 3 df; p = 0.005). Adjusted HR 2.30 (95% CI 1.12–4.75; p = 0.024).
Mentions: The impact of COX2 genotype and body size on early events in endocrine-treated patients with ER-positive tumors was investigated. Endocrine-treated patients with a breast volume ≥850 ml had an increased risk of early events compared to endocrine-treated patients with a breast volume <850 ml ( Fig. 4a; Log Rank 1 df; p = 0.006). C-allele carriers did not have a significantly increased risk of early events compared to G/G carriers ( Fig. 4b; Log Rank 1 df; p = 0.19). However, C-allele carriers with a breast volume ≥850 ml had an increased risk of early events ( Fig. 4c; Log Rank 3 df; p = 0.005). The results were not dependent on whether the patients had received aromatase inhibitors (AI) or tamoxifen. In a multivariate model, C-allele carriers with a breast volume ≥850 ml had a more than 2-fold increased risk of early events compared to GG carriers with a breast volume ≥850 ml (adjusted HR 2.30; 95% CI 1.12–4.75; p = 0.024).

Bottom Line: The COX2 rs5277 (306G>C) polymorphism has been associated with inflammation-associated cancers.Minor allele(C) frequency was 16.1%.Chemotherapy-treated G/G-carriers with a breast volume ≥ 850 ml had an increased risk of early events irrespective of ER status, adjusted HR 8.99 (1.14-70.89).

View Article: PubMed Central - PubMed

Affiliation: Division of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.

Show MeSH
Related in: MedlinePlus